Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Low-Dose Venetoclax Achieves Promising Results in AL Amyloidosis and Myeloma Subsets

August 5th 2021

Low-dose venetoclax monotherapy demonstrated antitumor activity in patients with heavily pretreated multiple myeloma and light chain amyloidosis harboring t(11;14).

BMS Withdraws Romidepsin Relapsed/Refractory PTCL Indication in the United States

August 3rd 2021

Bristol Myers Squibb has made the decision to withdraw in the indication for romidepsin as a monotherapy for the treatment of adult patients with peripheral T-cell lymphoma who have previously received at least 1 therapy.

Approaches to Treatment of Ph- ALL

August 3rd 2021

Ibrahim Aldoss, MD; and James K. McCloskey, MD, discuss how to approach the treatment of a pediatric or AYA patient with ALL who is Philadelphia chromosome-negative (Ph-).

Treating Ph+ ALL: The GIMEMA Trial

August 3rd 2021

A review of the design, results, and practical implications of the GIMEMA Trial.

Considerations in Mast Cell Disorders

August 2nd 2021

The panel of experts highlights the importance of assessing symptomology and clinical characteristics in mast cell disorders.

Systemic Mastocytosis: Epidemiology and Diagnostic Criteria

August 2nd 2021

Experts in the field of mast cell disorders discuss the epidemiology and diagnostic criteria of systemic mastocytosis.

Ivosidenib/Azacitidine Significantly Improves EFS in Previously Untreated IDH1-Mutated AML

August 2nd 2021

The combination of ivosidenib plus azacitidine significantly improved event-free survival compared with azacitidine plus placebo in previously untreated patients with IDH1-mutated acute myeloid leukemia, meeting the primary end point of the phase 3 AGILE trial.

DLBCL: Approaches to Treating Patients Ineligible for Transplant

August 2nd 2021

Key opinion leaders highlight treatment approaches for patients with DLBCL (diffuse large B-cell lymphoma) who are ineligible for transplant.

Data From the L-MIND Trial

August 2nd 2021

Greg Nowakowski, MD [Mayo Clinic, Rochester, Minnesota], reviews the data from the L-MIND trial of tafasitamab and lenalidomide for transplant-ineligible patients with R/R DLBCL (relapsed/refractory diffuse large B-cell lymphoma).

FDA Grants Fast Track Status to Eryaspase for Hypersensitive Acute Lymphocytic Leukemia

July 30th 2021

The FDA has granted a fast track designation to eryaspase for use as a potential therapeutic option in patients with acute lymphocytic leukemia who have developed hypersensitivity reactions to Escherichia coli–derived pegylated asparaginase.

Frontline Therapy for Patients With CLL: Testing and Risk Classification

July 30th 2021

A review of how frontline therapy selection for patients with CLL is informed by molecular testing, staging, and risk stratification amidst a multitude of other disease factors.

ESA Use in the Treatment of MDS

July 30th 2021

The panel of experts discusses considerations necessary when recommending treatment with erythropoiesis-stimulating agents in patients with myelodysplastic syndrome.

Impact of Targeted Therapy in CLL

July 30th 2021

Expert insight on the impact that targeted therapies have had on the frontline treatment landscape of chronic lymphocytic leukemia.

Guidelines for the Treatment of MDS

July 30th 2021

Rami Komrokji, MD, discusses his approach to treatment in patients with myelodysplastic syndrome, while being mindful of recommended guidelines.

Second-Generation FLT3 Inhibitors for Acute Myeloid Leukemia

July 29th 2021

A panel of thought leaders in AML examines single-agent and combination-based approaches using the second-generation FLT3 inhibitors gilteritinib, quizartinib, and crenolanib.

The Role of FLT3 Inhibitors for Treatment of AML

July 29th 2021

Experts in hematologic malignancies provide key insights into the use of FLT3 inhibitors and discuss whether it is possible to predict patients who may benefit from midostaurin + chemotherapy.

Enasidenib Elicits Clinical Efficacy in High-Risk, IDH2-Mutated MDS

July 29th 2021

The IDH2 inhibitor enasidenib demonstrated promising efficacy in combination with azacitidine and as a single agent in patients with high-risk, IDH2-mutated myelodysplastic syndrome.

Approaches to Treatment of Ph+ ALL

July 27th 2021

A discussion on how to approach the treatment of a pediatric or AYA (adolescent and young adult) patient with ALL (acute lymphoblastic leukemia) who is Philadelphia chromosome positive (Ph+ALL).

Risk Assessment in ALL

July 27th 2021

Ibrahim Aldoss, MD, and James K. McCloskey, MD, share their thoughts on different stratification measures used to assess risk in pediatric, adolescent, and young adult patients newly diagnosed with ALL.

Recommendations for Second-Line Therapy in DLBCL

July 26th 2021

Key opinion leaders discuss recommended second-line treatment options for patients with DLBCL.